突破性疗法-话题@MedSci

#突破性疗法#

77篇内容 | 2180人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1536201, encodeId=be951536201f0, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=AXS-05获得FDA突破性疗法认定，用于治疗阿尔茨海默症躁动, objectType=article, longId=196694, objectId=c5a019669464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5a019669464, replyNumber=0, likeNumber=96, createdTime=2020-06-30, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5a019669464, moduleTitle=AXS-05获得FDA突破性疗法认定，用于治疗阿尔茨海默症躁动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5a019669464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536200, encodeId=af5f1536200e6, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染, objectType=article, longId=195480, objectId=075d1954800a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=075d1954800a, replyNumber=0, likeNumber=68, createdTime=2020-06-10, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=075d1954800a, moduleTitle=口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=075d1954800a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536199, encodeId=8b41153619900, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=57, createdTime=2020-05-21, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536198, encodeId=57ce153619831, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=61, createdTime=2020-05-15, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536197, encodeId=5215153619ec5, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, objectType=article, longId=193124, objectId=e57a19312429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57a19312429, replyNumber=0, likeNumber=67, createdTime=2020-04-30, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57a19312429, moduleTitle=治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57a19312429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536196, encodeId=83821536196fb, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=肺动脉高压新药Sotatercept，获得FDA突破性疗法称号, objectType=article, longId=191907, objectId=1f2f19190e67, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f2f19190e67, replyNumber=0, likeNumber=56, createdTime=2020-04-11, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f2f19190e67, moduleTitle=肺动脉高压新药Sotatercept，获得FDA突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f2f19190e67)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536195, encodeId=60b6153619563, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, objectType=article, longId=190457, objectId=fbcc19045e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc19045e07, replyNumber=0, likeNumber=77, createdTime=2020-03-21, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc19045e07, moduleTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc19045e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536194, encodeId=f36715361947f, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, objectType=article, longId=189903, objectId=463418990337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463418990337, replyNumber=0, likeNumber=62, createdTime=2020-03-14, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463418990337, moduleTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463418990337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536193, encodeId=c3601536193b8, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, objectType=article, longId=188519, objectId=cccf188519dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cccf188519dd, replyNumber=0, likeNumber=79, createdTime=2020-02-22, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cccf188519dd, moduleTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cccf188519dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536192, encodeId=f05c153619221, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=FDA授予Molgradex突破性疗法认定，用于治疗自身免疫性肺泡蛋白沉着症, objectType=article, longId=185520, objectId=4701185520a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4701185520a4, replyNumber=0, likeNumber=52, createdTime=2020-01-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4701185520a4, moduleTitle=FDA授予Molgradex突破性疗法认定，用于治疗自身免疫性肺泡蛋白沉着症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4701185520a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536191, encodeId=b15d1536191ce, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, objectType=article, longId=184677, objectId=6ed31846e733, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed31846e733, replyNumber=0, likeNumber=60, createdTime=2019-12-14, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed31846e733, moduleTitle=中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed31846e733)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536190, encodeId=7cf615361909e, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=抗癌新药获FDA突破性疗法认定，临床试验正在招募, objectType=article, longId=180911, objectId=b5e0180911c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e0180911c6, replyNumber=0, likeNumber=62, createdTime=2019-10-12, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e0180911c6, moduleTitle=抗癌新药获FDA突破性疗法认定，临床试验正在招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e0180911c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536189, encodeId=f990153618915, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=58, createdTime=2019-10-06, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536188, encodeId=5b6d1536188d4, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定, objectType=article, longId=180107, objectId=1e3218010eb7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e3218010eb7, replyNumber=0, likeNumber=67, createdTime=2019-09-28, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e3218010eb7, moduleTitle=Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e3218010eb7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536187, encodeId=6a7c153618e2d, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, objectType=article, longId=178985, objectId=41461e898555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41461e898555, replyNumber=0, likeNumber=63, createdTime=2019-09-07, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41461e898555, moduleTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41461e898555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536186, encodeId=7b821536186fc, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=FDA授予肝癌突破性疗法：免疫+靶向治疗豪华组合疗法, objectType=article, longId=177000, objectId=742f1e7000ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=742f1e7000ae, replyNumber=0, likeNumber=80, createdTime=2019-08-07, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=742f1e7000ae, moduleTitle=FDA授予肝癌突破性疗法：免疫+靶向治疗豪华组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=742f1e7000ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536185, encodeId=95f41536185fc, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=Keytruda组合疗法治疗肝癌获FDA突破性疗法认定, objectType=article, longId=176162, objectId=c0101e61624e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0101e61624e, replyNumber=0, likeNumber=52, createdTime=2019-07-27, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0101e61624e, moduleTitle=Keytruda组合疗法治疗肝癌获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0101e61624e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536184, encodeId=72e5153618457, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, objectType=article, longId=166719, objectId=4a10166e19ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a10166e19ca, replyNumber=0, likeNumber=57, createdTime=2019-05-25, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a10166e19ca, moduleTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a10166e19ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=治疗精神分裂症：SEP-363856已获FDA突破性疗法认定, objectType=article, longId=165923, objectId=db6a165923d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db6a165923d4, replyNumber=0, likeNumber=55, createdTime=2019-05-14, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db6a165923d4, moduleTitle=治疗精神分裂症：SEP-363856已获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db6a165923d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536182, encodeId=f360153618209, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=肿瘤电场治疗在港上市，胶质母细胞瘤迎十年来突破性疗法, objectType=article, longId=161451, objectId=36bc161451e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36bc161451e8, replyNumber=0, likeNumber=53, createdTime=2019-03-02, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36bc161451e8, moduleTitle=肿瘤电场治疗在港上市，胶质母细胞瘤迎十年来突破性疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36bc161451e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性疗法

2020-05-29

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

AXS-05获得FDA突破性疗法认定，用于治疗阿尔茨海默症躁动

2020-06-30

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

口服小分子抑制剂Pritelivir获得FDA授予突破性疗法称号，用于治疗免疫功能低下的单纯疱疹病毒感染

2020-06-10

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2020-05-21

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-05-15

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

治疗特定肺癌患者，武田EGFR抑制剂获突破性疗法认定

2020-04-30

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

肺动脉高压新药Sotatercept，获得FDA突破性疗法称号

2020-04-11

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号

2020-03-21

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号

2020-03-14

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定

2020-02-22

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

FDA授予Molgradex突破性疗法认定，用于治疗自身免疫性肺泡蛋白沉着症

2020-01-02

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

中国药企再突破：自主研发细胞免疫疗法获美国突破性疗法认定

2019-12-14

docwu2019 (审核中...)

前往app查看评论内容

#突破性疗法#

抗癌新药获FDA突破性疗法认定，临床试验正在招募

2019-10-12

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定

2019-09-28

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定

2019-09-07

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

FDA授予肝癌突破性疗法：免疫+靶向治疗豪华组合疗法

2019-08-07

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

Keytruda组合疗法治疗肝癌获FDA突破性疗法认定

2019-07-27

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌

2019-05-25

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

治疗精神分裂症：SEP-363856已获FDA突破性疗法认定

2019-05-14

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

肿瘤电场治疗在港上市，胶质母细胞瘤迎十年来突破性疗法

2019-03-02

科室
- - 订阅+
  - 更多科室
工具
服务